MISSISSAUGA, ON, April 26, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announcedthat experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 19, 2018.
Dr. Rulleau is currently
"We're pleased to attract such a highly accomplished and recognized healthcare executive to the Cipher Board," said Mark Beaudet, Chair of Cipher's Board of Directors. "Laurence brings extensive transaction and industry experience that complements and strengthens Cipher's Board of Directors."
Dr. Rulleau commented: "I have known Cipher since its initial public listing, and I'm excited to join the Board at this important stage in the Company's evolution. Leveraging my background and relationships, I look forward to assisting the team as it continues to execute on the strategy to build a diversified portfolio of products across multiple therapeutic categories."
About Cipher Pharmaceuticals Inc.Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All